Ms. magazine  -- more than a magazine a movement

SIGN UP FOR MS. DIGEST, JOBS, NEWS AND ALERTS

FEMINIST WIRE NEWSBRIEFS

ABOUT
SEE CURRENT ISSUE
SHOP MS. STORE
MS. IN THE CLASSROOM
FEMINIST DAILY WIRE
FEMINIST RESOURCES
PRESS
JOBS AT MS.
READ BACK ISSUES
CONTACT
RSS (XML)
 
feminist wire | daily newsbriefs

July-24-13

Teva Pharmaceuticals Gets Exclusive Rights to OTC Emergency Contraception

The US Food and Drug Administration has given Teva Pharmaceuticals, the makers of brand name emergency contraception pill Plan B One-Step, exclusive rights to sell their product on store shelves without age restrictions for three years. Generic versions of pill will remain behind the counter and only be available to those 17 years of age or older.

Plan B One-Step costs approximately $50, whereas generic versions cost between $35 and $40. However, with the exclusive rights for Teva, the cost-effective versions will still be denied to young girls or those who do not have government issued identification, creating a barrier for many women and girls. Teva has promised to not increase the price of the drug while it has market exclusivity.

Janet Crepps, senior counsel at the Center for Reproductive Rights, told reporters "The FDA should have left open the option for all generic and potentially more affordable brands of emergency contraception to be made widely available, without delay."

The FDA cites clinical data Teva submitted in June that showed that Plan B One-Step could be safely taken by young teens as justification for exclusivity. Former FDA assistant commissioner for women's health, Susan Wood, told the Boston Globe, "The rationale behind exclusivity is that if a company does essential new research to get their product approved over-the-counter, they should get protection from generics for a little bit longer. But the data Teva was asked to collect wasn't actually essential, and now we're left in a confusing situation that makes it more expensive for women to get full access to emergency contraception."

In April, US District Judge Edward Korman ruled that the FDA must make single-pill versions of the morning-after pill available to women and girls of all ages and that it be made over the counter. Korman did not mandate that the restrictions be lifted from the two-pill versions. In June, the Obama Administration announced that it would not challenge the US Second Circuit Court's upholding of Korman's ruling.

Media Resources: Boston Globe 7/24/2013; ThinkProgress 7/23/2013; Feminist Newswire 6/11/2013, 6/5/2013, 4/5/2013


© Feminist Majority Foundation, publisher of Ms. magazine

If you liked this story, consider making a tax-deductible donation to support Ms. magazine.

 

 

Send to a Friend
Their
Your
Comments
(optional)


More Feminist News

1/28/2015 Senator Boxer Urges President to Continue Support for UN Population Fund - Earlier this week, Senator Barbara Boxer (D-CA) along with 21 of her Senate colleagues sent a letter to President Obama calling on him to maintain support for the United Nations Population Fund (UNFPA). UNFPA, which promotes maternal and reproductive health, conducts major demographic surveys, and campaigns against fistula and female genital mutilation, supports programs in over 150 countries. . . .
 
1/28/2015 Former Vanderbilt Football Players Found Guilty in Campus Sexual Assault Case - Two former students of Vanderbilt University have been found guilty of four counts of aggravated rape, one count of attempted aggravated rape, two counts of aggravated sexual battery, and one count of tampering with evidence and unlawful photography by a jury in Nashville yesterday. . . .
 
1/27/2015 Marissa Alexander To Be Released from Prison - Marissa Alexander is expected to be released from prison today, where she spent the last three years of her life after firing a warning shot into the air to defend herself from her estranged and abusive husband. . . .